Skip to main content

Table 2 Association between clinicopathological features and pCR in FEC-Taxotere treated group (N = 118)

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

 

Total

pCR (N = 25)

No pCR (N = 93)

P value

N = 118

n

%a

n

%a

Tumor size 

T0-T1

5

1

20.0

4

80.0

 

T2

60

16

26.7

44

73.3

 

T3

24

3

12.5

21

87.5

 

T4

27

4

14.8

23

85.2

NS

NA

2

1

 

1

  

Histopronostic grade

SBRI–SBRII

61

9

14.8

52

85.2

 

SBRIII

43

16

37.2

27

62.8

0.009*

NA

14

0

 

14

  

Nodal status

Positive

63

12

19.1

51

80.9

 

Negative

53

12

22.6

41

77.4

NS

NA

2

1

 

1

  

KI67

Positive

42

12

28.6

30

71.4

 

Negative

6

0

0.0

6

100.0

NS

NA

70

13

 

57

  

Hormone receptor status

RH

  Positiveb

77

12

15.6

65

84.4

 

  Negativec

39

13

33.3

26

66.7

0.003*

  NA

2

0

 

2

  

RE

  Positive

74

10

13.5

64

86.5

 

  Negative

42

15

35.7

27

64.3

0.005*

  NA

2

0

 

2

  

RP

  Positive

57

10

17.5

47

82.5

 

  Negative

58

15

25.9

43

74.1

NS*

  NA

3

0

 

3

  

Triple negative

  Yes

32

13

40.6

19

59.4

 

  No

75

12

16.0

63

84.0

0.006*

  NA

11

0

 

11

  
  1. NA not applicable, pCR pathological complete response.
  2. * Khi-2 test.
  3.  Fisher exact test.
  4.  Wilcoxon Mann–Whitney test.
  5. aPercentages of evaluable patients.
  6. bEstrogen receptor or progesterone receptor positive.
  7. cEstrogen receptor and progesterone receptor negative.